Navigation Links
FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
Date:3/1/2011

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)  

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough, and excessive phlegm. An exacerbation can last up to several weeks and result in lung function decline, increased risk of death, and may be associated with severe anxiety.

Cigarette smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute. COPD is the fourth leading cause of death in the United States.

Roflumilast, a new drug class for the treatment of COPD, is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). It is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis. Roflumilast is not intended to treat another form of COPD which involves primary emphysema.

"COPD is a serious disease that gets worse over time," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research. "New treatment options that reduce frequency of flare-ups or exacerbations are important in helping patients with COPD associated with chronic bronchitis and a history of exacerbations in managing this debilitating disease."

The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast. Those treated had a history of COPD associated with chronic bronchitis and had experienced an exacerbation of the disease during the 12 months prior to be
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is ... (FDA) issued a warning letter to C.R. Bard, the manufacturer ... taking adequate strides to correct violations the agency found at ... these violations after the FDA cited them during Inspectional Observations ... in Bard,s Tempe, AZ , location and ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... CAMBRIDGE, Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: ... discovery and development, focusing on the early diagnosis and ... that it has been selected by Windhover as one ... in the cardiovascular/metabolic category. This announcement is part of ...
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... (FDA) has approved the real-time PCR COBAS® TaqMan® ... on COBAS® TaqMan® technology to support hepatitis C ... help clinicians to more confidently and effectively monitor ...
Cached Medicine Technology:GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test 2Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test 3
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New ... and family members, medical professionals, and researchers, covering a variety of topics related ... a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... 2015”, one of the industry’s premier thought leadership symposiums, hosted by Massachusetts-based ... 6. The event attracts over 250 “C”-level executives, administrators, directors of nursing, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System ... that evaluate the potential of related, experimental treatments. The collaboration moves into the next ... award Columbia Care one of five state licenses to produce and dispense medical marijuana. ...
(Date:7/31/2015)... ... 31, 2015 , ... Like nearly every other form of surgery, it shouldn't ... more effective and less intrusive and painful. Leading these advances in the United ... Loria currently stands as the only doctor in the United States who is qualified ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a ... a heart rate of 150 beats versus 100 beats, this is a big deal," ... to give life back to patients with heart disease," he adds. People with angina ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... Protection Week March 1-7, 2009 FRAMINGHAM, Mass., March 2 ... the largest increase occurring at corporations and small businesses. ... that 86 percent of data breaches could be prevented, ... Protection Program ( www.identityforce.com/MPP ) in honor of National ...
... Calif., March 2 Based on its recent,analysis ... presents Veran,Medical Technologies, Inc. with the 2009 North ... the Year in recognition of its pioneering,development of ... known as,the IG4, which enables accurate and efficient ...
... System Cart Allows Easier Operation and Improved Workflow ... Traxtal Inc., the pioneer and world leader in ... newly designed system cart for the PercuNav interventional ... Booth # 322 of the Society of Interventional ...
... to new heightsHALIFAX, March 02 /PRNewswire/ - Ocean ... Omega-3 EPA/DHA food and dietary supplement ingredients from ... develop consumer awareness of the health benefits of ... awareness campaign with an interview segment ( http://www.onc.ca/Press/Docs/SEARS-WILLIAM-12.12.08.mp3 ...
... children ages 8-11 years shows contact lens wearers ... and Social Acceptance , JACKSONVILLE, Fla., March ... children beyond simply correcting their nearsightedness -- significantly ... acceptance among friends, and ability to play sports. ...
... software and services company, today announces that it has passed,the ... (TSU) 2009 label. , Misys was ... TSU service came into existence in April 2007 for its ... , The TSU, which has more ...
Cached Medicine News:Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 2Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 2Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 3Health News:Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System 4Health News:Traxtal to Introduce Next-Generation PercuNav System Cart at SIR Annual Scientific Meeting 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 2Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 3Health News:Dr. William Sears and Ocean Nutrition take flight on American Airlines to Spread Consumer Awareness of the Health Benefits of Omega-3 EPA/DHA 4Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 2Health News:Misys Wins SWIFTReady TSU 2009 Accreditation for Third Year Running 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: